BioLargo stock analysis
Want to see BLGO full AI Analyst Report?
BioLargo (BLGO) Stock Price & Analysis
BLGO Stock Chart & Stats
- Day’s Range
- $0.07 - $0.07
- 52-Week Range
- $0.06 - $0.20
- Previous Close
- $0.07
- Volume
- N/A
- Average Volume (3M)
- 451.21K
- Market Cap
- $22.76M
- Enterprise Value
- $39.76M
- Total Cash (Recent Filing)
- $2.19M
- Total Debt (Recent Filing)
- $6.39M
- Price to Earnings (P/E)
- ―
- Beta
- -0.05
- Next Earnings
- Nov 18, 2026 (Est.)
- EPS Estimate
- -0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Core Engineering Revenue Growth
Growth in the engineering business provides a durable operating foundation because it is tied to third-party environmental customers rather than only one emerging product. Management’s description of the business as growing and stable supports the potential for recurring service-led revenue and improved scale.
ViaCLYR Commercial Traction And Distribution
ViaCLYR’s use across hundreds of patients and favorable clinician feedback indicate early market validation for an FDA-cleared product. Broad distribution relationships and ongoing health-system evaluations could expand adoption over the next several quarters if approval and implementation processes continue.
PFAS Technology And Strategic Alliance
PFAS treatment addresses a substantial environmental need, while the first commercial installation and trial pipeline provide evidence of progression beyond research. Aquatech’s international reach may improve BioLargo’s ability to pursue larger projects and access customers without building the entire channel alone.
Bears Say
Shrinking Revenue And Severe Operating Losses
The revenue contraction and exceptionally negative operating margins show that the current cost structure remains far ahead of the business’s sales base. Unless commercialization produces sustained growth, continued losses can constrain investment, weaken operating leverage, and increase dependence on external capital.
Heavy Cash Burn And Negative Equity
Persistent cash outflows mean operations are not currently self-funding, while negative equity reduces financial flexibility and resilience. Continued reliance on financing can divert resources from growth initiatives and may create dilution or refinancing pressure if capital needs remain elevated.
Clyra Funding And Commercialization Risk
Clyra offers meaningful growth potential, but its disproportionate contribution to consolidated losses makes execution especially important. Additional fundraising is required before scale is proven, so delays in adoption or reimbursement could prolong cash consumption and increase pressure on the parent company.
BioLargo News
BioLargo subsidiary adds third distribution channel, accelerate ViaClyr rollout
BioLargo (BLGO) announced that its subsidiary Clyra Medical Technologies is expanding distribution of its FDA-cleared ViaClyr wound irrigation solution through a new Reseller Agreement with Spartan Medical, opening a dedicated
BioLargo joins NJIT-led PFAS Partnership Innovation Consortium
BioLargo (BLGO) has joined the New Jersey PFAS Partnership Innovation Consortium an NJIT-led initiative focused on accelerating the development, validation, and deployment of PFAS technologies. BioLargo also announced that Tonya
BioLargo preparing to relaunch CupriDyne-based consumer products
BioLargo (BLGO) is preparing to relaunch CupriDyne-based consumer pet products under a yet-to-be-announced brand. Targeting pets first, the new consumer products subsidiary will eventually expand into household odor and cleaning
BLGO FAQ
What was BioLargo’s price range in the past 12 months?
What is BioLargo’s market cap?
When is BioLargo’s upcoming earnings report date?
How were BioLargo’s earnings last quarter?
Is BioLargo overvalued?
Does BioLargo pay dividends?
What is BioLargo’s EPS estimate?
How many shares outstanding does BioLargo have?
What happened to BioLargo’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioLargo?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BioLargo
BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater purification, managing industrial odors and volatile organic compounds (VOCs), enhancing air quality, and controlling infections. Backed by numerous issued patents, BioLargo maintains a robust product pipeline and extends its expertise through comprehensive environmental engineering services. Among its notable innovations are the Advanced Oxidation system, a water treatment solution generating potent oxidative and energetic iodine species; the Aqueous Electrostatic Concentrator, specifically designed for eliminating PFAS from water; CupriDyne Clean industrial products, which effectively neutralize stubborn odors and VOCs across various industrial settings; and specialized advanced wound care products. Established in 1991, BioLargo, Inc. is headquartered in Westminster, California.
- Sector
- Basicmaterials
- Industry
- Chemicals - Specialty
- CEO
- Dennis Calvert
- Employees
- 45
- Website
- www.biolargo.com
- Address
- 14921 Chestnut Street, Westminster, CA, 92683, US
BioLargo (BLGO) Earnings & Revenues
BLGO Earnings Call
Earnings Call SentimentPositive
The call was strongly forward-looking and optimistic, emphasizing revenue growth in the core engineering business, multiple distribution channels for Clyra, PFAS commercial progress, new ventures, and potential contract opportunities. However, management also acknowledged a difficult year marked by a market capitalization decline of more than 60%, the loss of the Pooph business, a close to $4 million write-down, Clyra’s launch delay and burn rate, and ongoing financing and regulatory uncertainty. The number and strength of the stated achievements and initiatives outweighed the stated challenges.
View all BLGO earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 6 | 12 |
| Technical Analysis | 1 | 6 | 2 |
| Moving Averages | 2 | 0 | 10 |










